A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome

Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee – 11 November 2021

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang – 11 November 2021

Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients

Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.

LiverLearning®: 2021 Clinical Research Workshop - Part I and II: Basics of Navigating Artificial Intelligence in Liver Research

To introduce artificial intelligence in the management of liver disease for clinicians. This program spans several applications of AI in hepatology spanning administrative datasets, radiology, pathology and multi-omics. This interactive session will spur further dialogue and research into this field and provide a platform to build on for future CRW events.

LiverLearning®: 2021 AASLD/ASGE Endoscopy Course: Clinical Challenges and Practical Solutions at the Interface of Liver Disease and Endoscopy

The 2021 AASLD/ASGE Endoscopy Course at AASLD will foster discussions on the management of challenging clinical scenarios encountered by hepatologists and gastroenterologists that require endoscopic consideration. This evidence-based course includes expert opinions on potential knowledge gaps or clinical controversies. The session has a case-based, interactive format that emphasizes good clinical practice, emerging paradigms, innovation, and safety concerns.

LiverLearning®: 2021 General Hepatology Update

What pressing challenges do patients with advanced liver disease and/or liver cancer face as they consider treatment options with their physicians? Complex diseases must be managed by a multidisciplinary team to achieve optimal outcomes. At this program, faculty will review effective strategies to incorporate multidisciplinary approaches in the management of liver cancer, portal hypertension, and substance-use disorders.

LiverLearning®: 2021 Liver Cancer SIG: Advances in Molecular Therapies and Emerging Treatment in Advanced HCC

Hepatocellular carcinoma (HCC) management strategies have been revolutionized over the last five years. Combination therapies are now standard of care for advanced HCC patients, and novel emerging therapies are currently being tested and approved. At this exciting talk, experts will review the many opportunities to improve management, quality of life and outcomes of patients with advanced HCC.

Subscribe to